Mar 9, 2018
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Partnerships, Licensing, Investments and M&A Deals and Trends for December 2017 in Pharmaceuticals”
Pune, India - March 9, 2018 /MarketersMedia/ —
Overview
Multiple Sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection, and neurodegeneration within the central nervous system. It is the most common cause of non-traumatic neurological disability in young adults, afflicting at least 2.5 million people worldwide.
In most patients, the disease is characterized initially by episodes of reversible neurological deficits, which is often followed by progressive neurological deterioration over time. The precise etiology of MS remains incompletely elucidated, but it is believed to involve a complex interaction between various environmental and genetic factors.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031251-pharmapoint-multiple-sclerosis-global-drug-forecast-and-market-analysis-to-2026
Companies mentioned
Bayer
Biogen
Merck KGaA
Teva
Sanofi
Novartis
Roche
Actelion
Celgene
Major Highlight of the Report
The late-stage candidates include products from both established and emerging players with a wide range of mechanism of action (MOA). Progressive MS is a significant focus for product development, with 8 of the late-stage products targeting this patient group as an initial indication, such as protecting mitochondrial energy sources (idebenone), antioxidants (MD1003), promoting remyelination (opicinumab) and neuroprotection (ibudilast and laquinimod). There is currently a distinct lack of DMT options for patients with progressive MS subtypes, and patients remain significantly underserved. The majority of the Phase III candidates targeting RRMS are based on established MOAs, such as second generation S1P receptor modulators (ozanimod and ponesimod) or anti-CD20 mAbs (ofatumumab and ublituximab).
Multiple Sclerosis Major Outlook
Overview of MS: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized MS market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, PPMS and SPMS), forecast from 2016 to 2026.
Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. Promising candidates in Phase IIB or above were profiled.
Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Multiple Sclerosis - Competitive Analysis
Key players are making innovative developments in Multiple Sclerosis. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/3031251-pharmapoint-multiple-sclerosis-global-drug-forecast-and-market-analysis-to-2026
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Contact Info:
Name: Norah Trent
Email: [email protected]
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: WISEGUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Pune
Phone: +91 841 198 5042
For more information, please visit http://www.wiseguyreports.com
Source: MarketersMedia
Release ID: 311797
Leading artificial intelligence companies Anthropic, OpenAI, SpaceXAI, and Google face allegations of collusion after calls emerged for a coordinated slowdown in AI development, according to a civil lawsuit filed in a United States federal court on Friday.
Read moreA granddaughter in Ohio has stumbled on an old family photo that many believe proves that a time traveler visited California nearly six decades ago.
Read moreNASA said Friday that the agency had given SpaceX a $946 million contract to fly three more astronaut missions to the International Space Station (ISS), extending the company's crewed flights to the station through 2030.
Read moreGoogle’s Gemini hacked three companies in the first known breakout, after the model accessed the internet and breached external systems during an evaluation of its cybersecurity capabilities.
Read moreA security research company said Friday it managed to break into OpenAI's internal systems using the latest software from Anthropic, exposing how quickly the technology can carry out sophisticated cyberattacks.
Read moreThe Cyberspace Administration of China has drafted a set of guidelines to ensure healthy and safe internet use by minors, laying out a series of regulations for relevant service providers.
Read moreA third-party test company inadvertently gave internet access to Google’s Gemini and other artificial intelligence models during cybersecurity testing.
Read moreThe company is expected to reach $100 billion in annualized revenue this year, even as chief executive Dario Amodei calls for slowing down development of some advanced A.I. models.
Read moreChinese researchers have made early strides in pushing semiconductor processing nodes below 3-nm using older lithography technology, as more advanced extreme ultraviolet lithography (EUV) tools from ASML remain blocked under US sanctions. The breakthrough marks the latest progress in China’s drive to chart an alternative path to advanced chipmaking amid US export restrictions. Under current export control rules, Dutch equipment giant ASML is barred from selling its state-of-the-art EUV machines...
Read moreAI-TECH-OPENAI-FINANCIALS:OpenAI forecasts cash burn near $280 billion by 2030, FT reports
Read moreAs Australia considers barring the use of smart glasses in government offices, the BBC asks people in Sydney what they think.
Read moreYOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.
